Latest news with #diagnostics
Yahoo
2 days ago
- Business
- Yahoo
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
QIAGEN N.V. QGEN has announced a new partnership with South Korea-based GENCURIX, Inc. to develop oncology assays for use on the QIAcuityDx digital PCR (dPCR) platform. The molecular diagnostics company is the first development partner under QIAGEN's QIAcuityDx Partnering Program, designed to enable the generation of a broad menu of in-vitro diagnostics (IVD) assays on the QIAcuityDx Four platform, increasing access to digital PCR diagnostics. The latest development is expected to significantly boost the company's Precision Diagnostics business under the Diagnostic Solutions product group. Shares of QIAGEN stayed flat in the aftermarket following the announcement of the news yesterday. The collaboration with GENCURIX represents the first step in building a robust and innovative assay ecosystem for the QIAcuityDx platform, backed by QIAGEN's distribution capabilities and technical support. Accordingly, market sentiment surrounding QGEN stock should stay positive, driven by the news. QIAGEN has a market capitalization of $10.35 billion. The company has an earnings yield of 5%, well above the industry's -29.3% yield. In the trailing four quarters, it delivered an average earnings surprise of 4.9%. The QIAcuityDx Partnering Program aims to support third-party assay development on QIAcuityDx. A member of the QIAcuity family of dPCR systems, the platform had more than 2,700 cumulative placements since its launch by the end of 2024. These menu initiatives for clinical applications will leverage this installed base and build on the 2024 milestone of launching more than 130 new assays for QIAcuity for research applications, complemented by the extensive menu of custom assays available on QIAGEN's GeneGlobe platform. Image Source: Zacks Investment Research Under this first partnership, GENCURIX will apply its proven expertise in complex, multiplex IVD assay development to create oncology tests. GENCURIX will begin developing multiple oncology assays and pursue IVD regulatory approvals. As the legal manufacturer of the assays, GENCURIX will be fully responsible for obtaining and maintaining all necessary regulatory approvals and certifications. Upon approval, the assays will be marketed through QIAGEN's global commercial infrastructure as part of the QIAcuityDx Partnering Program, ensuring streamlined access for laboratories worldwide. Per a research report, the global IVD market was valued at $108.30 billion in 2024 and is expected to grow at a compound annual rate of 5.6% through 2030. The growing demand for accurate, rapid and personalized diagnostic solutions globally is fueling the market's growth. The expansion is also supported by the integration of digital health, AI and data analytics into diagnostic platforms, helping enhance test accuracy and clinical decision-making. Last week, the company announced a new global collaboration with Incyte to develop a novel diagnostic panel to support the latter's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Under the agreement terms, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. Over the past year, QGEN shares have risen 8.1% against the industry's 16.1% decline. QIAGEN currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Hims & Hers Health HIMS and Cencora COR. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Cencora each carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 5.2% to $2.04 in the past 30 days. Shares of the company have rallied 35.1% in the past year compared with the industry's 7.7% growth. Its earnings yield of 8.5% compares comfortably with the industry's 0.5% yield. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health shares have surged 172.8% in the past year. Estimates for the company's 2025 earnings per share have jumped 2.8% to 73 cents in the past 30 days. HIMS' earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Cencora's fiscal 2025 earnings per share have increased 0.4% to $15.75 in the past 30 days. Shares of the company have jumped 25.9% in the past year against the industry's 16.2% fall. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. In the last reported quarter, it delivered an earnings surprise of 8.3%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
2 days ago
- Health
- Associated Press
NeuralCure AI Launches the First Diagnostic & Digital Twin OS for Preventative Care Clinics
Powering the $600B+ Patient-Led Healthcare Revolution DENVER, June 19, 2025 /PRNewswire/ -- NeuralCure AI today announced the official launch of its groundbreaking Diagnostic & Digital Twin Operating System, the first infrastructure platform purpose-built for the exploding preventative, regenerative, and patient-led healthcare market. As millions of Americans take control of their health, ordering their own labs and imaging, using AI to self-navigate symptoms, and bypassing traditional gatekeepers, a new healthcare economy is forming, and it is projected to reach $590B+ by 2029. NeuralCure AI is stepping in to ensure this future is safe, scalable, and intelligent. 'This market is happening with or without the old system, and there's no putting the cat back in the bag,' said Orin Wilson, CEO of NeuralCure AI. 'Patients are leading the charge. NeuralCure is the infrastructure that ensures this revolution actually works.' Rising Distrust in Healthcare Is Fueling Patient-Led Models Over the past several years, public confidence in traditional healthcare systems has seen a significant shift. High-profile treatment errors, inconsistent guidance during the pandemic, and ongoing debates around vaccine safety and pharmaceutical influence have caused many patients to seek more control over their own care. Surveys by Gallup and Pew Research show a decline in institutional trust in healthcare providers and public health authorities, especially among younger generations and self-pay patients. At the same time, there's been a surge in demand for tools that allow individuals to proactively manage their health, interpret their own data, and explore personalized treatment paths outside of insurance-based medicine. This growing skepticism hasn't led to disengagement, it's led to empowered participation. Patients are now: 'Patients today want transparency, autonomy, and intelligence in their care,' said Orin Wilson, CEO of NeuralCure AI. 'They're not opting out of healthcare, they're opting into something better. Our job is to support that shift with the right infrastructure.' NeuralCure AI is responding to this demand by building systems that combine medical-grade intelligence with real-time, patient-facing accessibility, helping both patients and clinics navigate this new era of care with more confidence and fewer blind spots. Introducing the Diagnostic & Digital Twin OS NeuralCure AI's OS is designed to power the full lifecycle of modern, cash-pay, and AI-enabled healthcare clinics with: 'This is the Stripe moment for healthcare,' said John Glenn, Head of Product. 'Just like Stripe built the OS for internet commerce, we're building the Diagnostic & Digital Twin OS for patient-powered care. Everyone else is building tools. We're building the layer those tools plug into.' The Rise of Patient-Powered Clinics Startups like Function Health, Wild Health, Levels, Tally Health, and Prenuvo have shown massive consumer demand for preventative, longevity, and self-directed care. The space remains fragmented, risky, and unregulated, with most clinics cobbling together systems not built for this model. NeuralCure AI is the first to bring infrastructure-level intelligence to the space, enabling precision, safety, and scale from day one. How Market Demand Is Driving NeuralCure AI's Growth The growth of NeuralCure AI is closely tied to the structural changes happening across preventative and cash-pay healthcare. As more clinics shift toward self-directed, out-of-pocket care models, they face a consistent set of challenges: fragmented data, lack of diagnostic infrastructure, and inefficient workflows not designed for this new care model. NeuralCure AI was built to address those gaps. The company is seeing increased adoption from clinics focused on early detection, regenerative therapies, imaging, and personalized care, many of which operate without traditional insurance billing or EHR systems. 'Most of the traction we're seeing is a direct response to operational needs from clinics already serving this market,' said Orin Wilson, CEO of NeuralCure AI. 'They need infrastructure that's purpose-built for how healthcare is actually being delivered now.' Backed by Forum Ventures NeuralCure AI is backed by Bad Ventures and Forum Ventures, an early-stage fund and accelerator focused on building companies solving meaningful problems in healthcare and enterprise software. Their support has helped guide NeuralCure's go-to-market strategy and early traction. About NeuralCure AI NeuralCure AI is the infrastructure company powering the future of patient-led healthcare. As the first Diagnostic & Digital Twin Operating System for preventative and regenerative clinics, we help clinics deliver safer, smarter, and more scalable care, on the patient's terms. For inquiries: [email protected] View original content to download multimedia: SOURCE NeuralCure AI, Inc.
Yahoo
2 days ago
- Health
- Yahoo
HLTH Inc. Unveils HLTH.rad — A Bold New Global Gathering for Imaging Innovators Co-Located with HLTH Europe 2026 in Amsterdam
AMSTERDAM, Netherlands, June 19, 2025 (GLOBE NEWSWIRE) -- HLTH Inc., the leading global platform for health innovation, is proud to announce the launch of a groundbreaking new event that will redefine the future of medical imaging, diagnostics, and radiology. Set to take place 17–18 June 2026 in Amsterdam, and co-located with the region's leading health innovation event, HLTH Europe, is designed to spotlight the next wave of imaging breakthroughs — from AI-driven diagnostics and machine learning to quantum imaging and precision medicine. is where the imaging revolution begins. Hosted in a purpose-built 2,050m² venue directly connected to HLTH Europe, will deliver: Two days of future-focused programming 100+ visionary speakers and trailblazers Hands-on workshops, roundtables & tech demos 20+ cutting-edge exhibitors & startups Curated cross-event networking with HLTH Europe attendees 'We are standing on the precipice of a new era in medical imaging,' said Jon Weiner, CEO of HLTH Inc. ' will serve as the nexus where innovation meets implementation, uniting pioneers in radiology, imaging, and diagnostics from around the globe to push the field forward.' Whether you're a radiologist, technologist, digital health disruptor, investor, or healthcare leader, offers the unmatched opportunity to engage with decision-makers, explore bleeding-edge solutions, and shape what's next in imaging. Are you ready to join the imaging revolution? Learn more at About HLTHHLTH Inc. is the catalyst igniting global healthcare transformation. We unite visionaries, innovators, and leaders to revolutionize health worldwide. Through our dynamic ecosystem of community, events, content, and initiatives, we spark groundbreaking collaborations that drive meaningful change. At HLTH, we're not just reimagining healthcare – we're actively building a future where equitable, accessible, and innovative health solutions are a reality for all. MEDIA CONTACTRobbie DoriusHead of Mediamedia@ in to access your portfolio
CNET
4 days ago
- Health
- CNET
Stay on Top of These 6 Blood Tests to Make Sure You're Monitoring Your Health
Having your blood drawn might not be much fun, but regular diagnostic tests of your blood can detect diseases early for treatment and give your doctor and medical providers critical information about how well your body is functioning. The proper frequency of these blood tests depends on your age and personal health status -- the most important thing is to ask your doctor which tests you need and when you need them. With all the different types of blood tests out there, it's good to go into your health care provider with a sense of what the most popular tests do and how they work. To help you out, we spoke with doctors for their expert insights about some important blood tests you may want to talk to your doctor about. 1. Complete blood count The complete blood count routine test provides a snapshot of your body's blood production and immunity. The test measures a variety of components in your blood, including red blood cells, white blood cells and platelets. Dr. Soma Mandal, a board-certified internist at Summit Health in New Providence, New Jersey, says that getting a CBC test is "recommended for individuals of all ages as part of a routine health examination or when symptoms suggest a potential health issue." Dr. Maria Knöbel, medical director of Medical Cert UK, agrees that this foundational test is appropriate for many patients. She says the test is ideal for anyone undergoing a routine health check-up. Still, she advises that you may want to get it if you're "experiencing symptoms like persistent fatigue, unexplained bruising or frequent infections." A CBC blood test can indicate lots of things, including: Allergies Anemia Certain cancers Heart disease Immune system disorders Infection Inflammation Iron deficiency Leukemia Low platelets (can affect blood clotting) Risk of clotting and bleeding Vitamin deficiency Mandal explains that each lab may have slight variations for what they consider "normal" test results. The ranges typically accepted as normal for adults are: Red blood cells: 4.5-5.9 million cells per microliter (men), 4.1-5.1 million cells per microliter (women) White blood cells: 4,500-11,000 cells per microliter Hemoglobin: 13.8-17.2 grams per deciliter (men), 12.1-15.1 grams per deciliter (women) Hematocrit: 40.7%-50.3% (men), 36.1%-44.3% (women) Platelets: 150,000-450,000 platelets per microliter 2. Lipid panel Lipids are fats and fatty substances in your blood. One type of lipid is cholesterol, which is used as a source of energy. Too much "bad" cholesterol (low-density lipoprotein or LDL) can damage your heart. You may need to get this test if you have cardiovascular disease or other risk factors. Mandal states this test is essential for anyone "at risk of cardiovascular diseases, including those with a family history of heart disease, smokers, people with hypertension or those who are overweight." Knöbel explains that a lipid panel measures total cholesterol and also breaks it down into HDL/LDL: Triglycerides LDL (bad cholesterol) HDL (good cholesterol) She says, "Elevated LDL levels are associated with an increased risk of heart disease, while high HDL levels are generally protective. Elevated triglycerides can also indicate a risk for heart disease and may be associated with other conditions like diabetes." The normal parameters for a lipid panel in adults are: Total cholesterol: Less than 200 mg/dL LDL cholesterol: Less than 100 mg/dL HDL cholesterol: 40 mg/dL or higher (men), 50 mg/dL or higher (women) Triglycerides: Less than 150 mg/dL3. Basic metabolic panel The basic metabolic panel (BMP) measures what Knöbel calls "critical aspects of your body's chemistry." This includes glucose, calcium and electrolytes such as sodium, potassium and bicarbonate. The test also looks for kidney function indicators, such as blood urea nitrogen and creatinine. "Glucose levels provide insight into blood sugar control," Knöbel explains. "Electrolyte imbalances can reveal issues related to dehydration, kidney disease or metabolic imbalances. Abnormal calcium levels can indicate issues with bone health or parathyroid function." BMP is often part of a routine exam. It also may be recommended for patients with diabetes or kidney disease or those at risk for these conditions. The results of your BMP could indicate: Dehydration Deteriorating bone health Diabetes Hypertension Kidney disease For adults, Mandal says the normal ranges for results of this test are: Bicarbonate: 23-30 mEq/L Blood urea nitrogen (BUN): 7-20 mg/dL Calcium: 8.5-10.2 mg/dL Chloride: 96-106 mEq/L Creatinine: 0.6-1.3 mg/dL Glucose: 70-99 mg/dL (fasting) Potassium: 3.5-5.0 mEq/L Sodium: 135-145 mEq/L 4. Hemoglobin A1C The Hemoglobin A1C test, also called the HbA1c, is a blood test that measures your average blood sugar level over the past 2-3 months. Mandel explains that it's primarily used to diagnose and monitor diabetes and pre-diabetes. If you're overweight, have symptoms of diabetes, have a family history of diabetes or are over the age of 45, the doctor says you may also want to get this test. A daily sugar test gives you a short-term view of your blood sugar level. On the other hand, this test is a long-term view of how well your body is managing glucose. Getting an HbA1c test could reveal a few things about your health: Diabetes Poor blood sugar control (higher risk of diabetes-related complications) Pre-diabetes Normal ranges for test results are: Normal: Less than 5.7% Pre-diabetes: 5.7% to 6.4% Diabetes: 6.5% or higher 5. Thyroid function tests If you are experiencing fatigue, weight changes, irregular heartbeat, hair loss or mood swings, you may want to get a thyroid function test. Typically prescribed only if you display symptoms such as those previously mentioned, this test measures the amount of thyroid-stimulating hormone in your blood. Your doctors can use the results to see how well your thyroid (a small, hormone-releasing gland in the front of your throat) is functioning. Mandal tells us this test is commonly included in routine health screenings, especially in women older than 60. Your blood test may indicate: High TSH levels/hypothyroidism (an underactive thyroid) Low TSH levels/hyperthyroidism (an overactive thyroid) Abnormal levels of T3 and T4 (other thyroid disorders) Doctors typically consider the following normal ranges for test results in adults: TSH levels: 0.4-4.0 mIU/L Free T4 levels: 0.8-1.8 ng/dL Free T3 levels: 2.3-4.2 pg/mL 6. 25-hydroxy vitamin D According to Mount Sinai, a hospital system in New York, some older patients can benefit from getting a 25-hydroxy test to check their vitamin D levels. People who are older than 65, have osteoporosis, get limited sun exposure and/or have celiac disease, Crohn's disease or ulcerative colitis may benefit from the test. Most people get ample vitamin D from the sun. Both skin production and gut absorption of the vitamin declines as we age. It's important to find out if you don't have enough vitamin D because it helps with everything from bone health to immunity and energy levels. The 25-hydroxy vitamin D will reveal two things: 25 hydroxy vitamin D3 (cholecalciferol) 25 hydroxy vitamin D2 (ergocalciferol) There is some disagreement among doctors about what a healthy range is for vitamin D but one generally accepted range is 20 and 40 ng/mL. Blood test FAQs Why are blood tests important? Blood tests are important because they can help doctors monitor your health and the effectiveness of treatments. They can also help doctors diagnose different medical conditions and determine the best treatment path. If my blood tests are normal, could I still have cancer? Routine blood tests may not be able to detect most types of cancer so even if your blood tests come back normal, you could still have cancer. Cancers also require additional diagnostic and laboratory testing for confirmation. If you're concerned about a certain type of cancer, discuss this with your doctor. Which blood tests need to be fasting? According to Harvard Health, fasting is often advised before tests such as glucose (blood sugar) and triglycerides, the latter of which is part of the cholesterol or lipid panel. Consult your doctor if you're confused about how long you should fast before your blood tests. The bottom line It's always important to discuss your health and any related concerns with your doctor before requesting any type of test. Based on your personal situation and health plan, your doctor may request blood work not on this list or say that you don't need some of the above tests. As a general rule, many people can benefit from CBC, lipid panel, BMP and hemoglobin A1C even without any symptoms. Also, thyroid function and vitamin D tests should be considered if you experience any symptoms. If you're older, you may also want to talk to your physician about your vitamin D absorption. If your labs are abnormal, you may need additional screening and more frequent repeat labs. If your labs are normal, these labs may only need to be repeated once a year while doing your annual exam with your primary doctor.
Yahoo
4 days ago
- Business
- Yahoo
In-vitro Diagnostics (IVD) Reagents Market Research 2025-2030: Innovation and Intensified Competition Drive Growth Amid Rising Demand for Early Diagnosis and Personalized Medicine
The global In-vitro Diagnostics (IVD) Reagents Market is set to grow from USD 77.56 billion in 2024 to USD 96.17 billion by 2030, at a CAGR of 3.65%. Key trends include biomarker discovery, POC testing, and AI automation. North America leads the market, with major players like Abbott, Danaher, and Roche driving innovation. In-vitro Diagnostics (IVD) Reagents Market Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "In-vitro Diagnostics (IVD) Reagents Market - Global Outlook & Forecast 2025-2030" report has been added to In-vitro Diagnostics (IVD) Reagents Market was valued at USD 77.56 Billion in 2024, and is projected to reach USD 96.17 Billion by 2030, rising at a CAGR of 3.65% The report considers the present scenario of the global IVD reagents market and its market dynamics for 2025-2030. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry. The global IVD reagents market is highly competitive and dynamic within the broader medical diagnostics industry. As healthcare systems increasingly rely on early disease detection, personalized medicine, and point-of-care testing, the demand for reliable and innovative IVD reagents has surged. This demand has led to intensified competition among global players, characterized by innovation, strategic alliances, aggressive market expansion, and pricing pressure. Furthermore, as consumer demand for convenience grows, companies in the IVD reagents market will compete to develop user-friendly, self-testing kits that offer lab-quality results at home. Companies will increasingly focus on targeted diagnostics for specific populations, diseases, or genetic profiles, creating competition in highly specialized niches. Emerging technologies like biosensors, nanotechnology, and lab-on-a-chip platforms will be central to next-gen reagent development and will define future competitive global IVD reagents market is fiercely competitive, shaped by constant innovation, evolving healthcare needs, and emerging technologies. Major players are leveraging product development, global expansion, strategic collaborations, and digital integration to strengthen their market position. However, this rapidly evolving landscape also presents challenges such as regulatory compliance, cost pressures, and technological disruptions. Looking ahead, companies that prioritize agility, innovation, and localized strategies will be best positioned to lead and thrive in the future of Danaher, F. Hoffmann-La Roche, Siemens Healthineers, and Thermo Fisher Scientific are among the key players shaping the global in vitro diagnostics (IVD) reagents market. Abbott stands out as a global leader in this space, offering a comprehensive portfolio of reagent-based solutions across its core laboratory, molecular, point-of-care, and rapid diagnostics segments. Leveraging advanced platforms such as ARCHITECT, Alinity, and ID NOW, Abbott delivers high-throughput and rapid diagnostic capabilities in areas including immunoassays, clinical chemistry, infectious disease detection, and cardiac biomarkers. Its extensive global footprint, strong R&D investments, and established presence in both mature and emerging markets firmly position Abbott as a dominant force in the IVD reagents TRENDS & DRIVERS Rising Significance of Biomarker Discovery & Companion DiagnosticsThe expanding importance of biomarker discovery and companion diagnostics is reshaping the IVD reagents market. As personalized medicine continues to advance, the demand for high-quality reagents that enable precise biomarker detection and CDx assays is on the rise. Market players who invest in innovative reagent development, form strategic partnerships, and expand into emerging applications will be well-positioned to capitalize on this growing sector. In a time where precision diagnostics is becoming the gold standard, IVD reagent manufacturers have a critical role to play in shaping the future of of Point-of-Care (POC) TestingPoint-of-care testing is transforming the diagnostic landscape, leading to a surge in demand for high-quality IVD reagents. With the emergence of decentralized, rapid, and personalized healthcare diagnostics, reagent manufacturers have an opportunity to expand their market presence through innovation. The growing demand for POC testing is being met by companies, that are utilizing advanced molecular reagents, multiplex testing solutions, and digital-friendly diagnostic Demand for Customized Diagnostic Tests & Personalized MedicineThe increasing demand for customized diagnostic tests and personalized medicine is shaping the future of the global IVD reagents market. With advancements in molecular diagnostics, AI-driven testing, and regulatory support for precision medicine, the market is poised for strong growth. Companies that invest in innovation, strategic collaborations, and emerging market expansion will be well-positioned to capitalize on the growing demand for customized IVD of AI and Automation in DiagnosticsAs laboratories and healthcare providers increasingly adopt AI-driven systems, the demand for high-quality, automation-friendly IVD reagents will continue to rise. While ongoing technological advancements and strategic collaborations will drive innovation, positioning AI-powered diagnostics as a cornerstone of the future healthcare landscape. Manufacturers that embrace AI-compatible reagent development will be well-positioned to capitalize on this growing market Prevalence of Chronic & Infectious DiseasesThe increasing prevalence of chronic and infectious diseases is a key driver of the global IVD reagents market. The demand for accurate, fast, and cost-effective diagnostic solutions continues to grow, supported by technological advancements and rising healthcare investments. Specifically in emerging economies and personalized medicine applications. Moving forward, innovation in reagent development will play a crucial role in shaping the future of diagnostic Awareness & Early Disease DetectionThe global IVD reagents market is experiencing robust growth due to rising awareness about early disease detection and preventive healthcare. The increasing prevalence of chronic and infectious diseases, coupled with advancements in diagnostic technologies, is driving demand for high-quality IVD reagents. Government initiatives, home-based testing trends, and rapid innovation in molecular diagnostics are further fueling industry in Reagent FormulationsAdvances in molecular reagents, lyophilized formulations, automation-friendly solutions, nanotechnology, and eco-friendly alternatives are enhancing diagnostic accuracy, efficiency, and accessibility. Continued R&D and strategic collaborations will accelerate innovation, shaping the future of the IVD industry. As the demand for high-performance diagnostics continues to rise, the market for advanced IVD reagents is poised for substantial growth in the coming Healthcare Infrastructure & Investments in R&DThe global IVD reagents market is witnessing robust growth, fueled by expanding healthcare infrastructure and increased investments in R&D. As healthcare systems worldwide focus on early disease detection and precision diagnostics, the demand for innovative and high-quality reagents will continue to rise. Ongoing technological advancements and strategic collaborations will drive further industry expansion, ultimately improving healthcare outcomes on a global scale. IVD REAGENTS MARKET GEOGRAPHICAL ANALYSISNorth America holds the largest share of the global IVD reagents market in 2024, accounting for over 38%. The North American IVD reagents market is one of the most advanced and rapidly growing segments in the global healthcare industry. Driven by technological advancements, rising chronic disease prevalence, and increasing demand for rapid and accurate diagnostics, the region holds a significant share of the global market. The U.S. and Canada, with their well-established healthcare infrastructure and strong regulatory frameworks, are key contributors to industry growth. Moreover, the rising prevalence of cancer, diabetes, cardiovascular diseases, and infectious diseases is fueling demand for advanced diagnostic reagents in the region. An aging population requires frequent diagnostic testing for chronic disease management and early disease is the second-largest market in the global IVD reagents market, driven by strong diagnostic research, widespread adoption of IVD regulations (IVDR), and increased funding for healthcare innovation. Germany, France, Russia, and Italy lead in industry share due to robust laboratory infrastructure and government support for early disease detection. Furthermore, APAC is the fastest-growing market in the global IVD reagents market during the forecast period, driven by rising healthcare investments, increasing prevalence of chronic diseases, and a growing middle-class population. Countries like China, Japan, and India are major contributors due to expanding healthcare access and government initiatives for disease screening. Latin America and the Middle East & Africa are emerging IVD reagents markets with strong potential, driven by rising healthcare investments and the need for improved diagnostics. Key Attributes: Report Attribute Details No. of Pages 354 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $77.56 Billion Forecasted Market Value (USD) by 2030 $96.17 Billion Compound Annual Growth Rate 3.6% Regions Covered Global Market Dynamics Opportunities & Trends Rising Significance of Biomarker Discovery & Companion Diagnostics Rise of Point-Of-Care (Poc) Testing Increasing Demand for Customized Diagnostic Tests & Personalized Medicine Expansion of AI and Automation in Diagnostics Market Growth Enablers Growing Prevalence of Chronic & Infectious Diseases Growing Awareness & Early Disease Detection Innovations in Reagent Formulations Expanding Healthcare Infrastructure & Investments in R&D Market Restraints High Cost of Advanced Diagnostic Tests Supply Chain Disruptions & Raw Material Shortages Stringent Regulatory Requirements Key Company Profiles Abbott Danaher F. Hoffmann La-Roche Siemens Healthineers Thermo Fisher Scientific Other Prominent Vendors Atomo Diagnostics Accelerate Diagnostics Agilent Technologies altona Diagnostics Amoy Diagnostics ARKRAY AccuBioTech The Binding Site Group BD Bio-Rad Laboratories BIOMERIEUX bioLytical Laboratories Biocartis Biocept Biomerica Bioway Biological Technology Boule Diagnostics Cupid Chembio Diagnostics CPC Diagnostics CPM Scientifica DIALAB GmbH DiaSorin S.p.A. Diagon EDAN Instruments Illumina Merck KGaA MP Biomedicals OraSure Technologies QIAGEN QuidelOrtho For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment In-vitro Diagnostics (IVD) Reagents Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
